These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 24615356

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J, Kriegs M, Zenker M, Heldt JM, Eke I, Pietzsch HJ, Grénman R, Cordes N, Petersen C, Baumann M, Steinbach J, Dikomey E, Kasten-Pisula U.
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I, Ingargiola M, Förster C, Kunz-Schughart LA, Baumann M, Runge R, Freudenberg R, Kotzerke J, Heldt JM, Pietzsch HJ, Steinbach J, Cordes N.
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [Abstract] [Full Text] [Related]

  • 4. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.
    Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, Baumann M, Steinbach J, Rodemann HP.
    Strahlenther Onkol; 2012 Sep; 188(9):823-32. PubMed ID: 22875052
    [Abstract] [Full Text] [Related]

  • 5. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
    Koi L, Bergmann R, Brüchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M.
    Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
    [Abstract] [Full Text] [Related]

  • 6. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW, Scott AM.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [Abstract] [Full Text] [Related]

  • 7. Effect of cetuximab and fractionated irradiation on tumour micro-environment.
    Santiago A, Eicheler W, Bussink J, Rijken P, Yaromina A, Beuthien-Baumann B, van der Kogel AJ, Baumann M, Krause M.
    Radiother Oncol; 2010 Nov 01; 97(2):322-9. PubMed ID: 20667608
    [Abstract] [Full Text] [Related]

  • 8. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM, Harari PM.
    Clin Cancer Res; 2000 Jun 01; 6(6):2166-74. PubMed ID: 10873065
    [Abstract] [Full Text] [Related]

  • 9. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F.
    Mol Pharm; 2014 Mar 03; 11(3):800-7. PubMed ID: 24472064
    [Abstract] [Full Text] [Related]

  • 10. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM, Huang SM.
    Int J Radiat Oncol Biol Phys; 2001 Feb 01; 49(2):427-33. PubMed ID: 11173137
    [Abstract] [Full Text] [Related]

  • 11. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
    Krause M, Schütze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M.
    Radiother Oncol; 2005 Feb 01; 74(2):109-15. PubMed ID: 15734198
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
    Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ.
    Cancer Biother Radiopharm; 1999 Dec 01; 14(6):451-63. PubMed ID: 10850332
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
    Huang SM, Bock JM, Harari PM.
    Cancer Res; 1999 Apr 15; 59(8):1935-40. PubMed ID: 10213503
    [Abstract] [Full Text] [Related]

  • 18. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS, Hong WK.
    Semin Oncol; 2002 Oct 15; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [Abstract] [Full Text] [Related]

  • 19. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW.
    Eur J Nucl Med Mol Imaging; 2010 Jul 15; 37(7):1368-76. PubMed ID: 20155263
    [Abstract] [Full Text] [Related]

  • 20. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A, Ansell A, Johansson AC, Roberg K.
    J Oral Pathol Med; 2013 Jan 15; 42(1):26-36. PubMed ID: 22643066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.